Seven Fleet Capital Management LP acquired a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,085,398 shares of the biotechnology company's stock, valued at approximately $4,070,243,000. CytomX Therapeutics makes up 0.7% of Seven Fleet Capital Management LP's investment portfolio, making the stock its 28th largest holding. Seven Fleet Capital Management LP owned 0.50% of CytomX Therapeutics at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the stock. Wells Fargo & Company MN increased its holdings in CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company's stock worth $28,000 after buying an additional 3,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in CytomX Therapeutics in the fourth quarter valued at $35,000. Lido Advisors LLC bought a new position in shares of CytomX Therapeutics in the 1st quarter valued at about $49,000. May Hill Capital LLC bought a new position in shares of CytomX Therapeutics in the 4th quarter valued at about $46,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of CytomX Therapeutics in the 1st quarter valued at about $52,000. Institutional investors and hedge funds own 67.77% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a "sell (d)" rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. Wolfe Research started coverage on CytomX Therapeutics in a research report on Tuesday, May 19th. They set an "outperform" rating and a $6.00 price target on the stock. Zacks Research lowered CytomX Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. HC Wainwright cut their price objective on CytomX Therapeutics from $17.00 to $11.00 and set a "buy" rating for the company in a research report on Monday, May 11th. Finally, Guggenheim reduced their target price on CytomX Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, CytomX Therapeutics has an average rating of "Moderate Buy" and an average price target of $11.90.
View Our Latest Research Report on CTMX
CytomX Therapeutics Stock Performance
CTMX opened at $3.32 on Thursday. The stock has a fifty day moving average of $3.44 and a 200-day moving average of $4.05. The company has a market capitalization of $723.43 million, a P/E ratio of -6.64 and a beta of 2.12. CytomX Therapeutics, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $8.21.
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The business had revenue of $1.42 million during the quarter, compared to analyst estimates of $12.39 million. On average, equities research analysts predict that CytomX Therapeutics, Inc. will post -0.4 earnings per share for the current fiscal year.
About CytomX Therapeutics
(
Free Report)
CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.
At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.
Featured Stories
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
